TL;DR
- 1.People with one gene variant lost weight 58% faster on semaglutide than those without it — same drug, same dose, wildly different results.
- 2.Your dopamine processing speed is the #1 genetic input for anyone considering brain-boosting peptides like semax or selank.
- 3.If your body's built-in antioxidant defense is genetically low, you have the most to gain from peptides like GHK-Cu and SS-31.
- 4.About 20-30% of people have a brain growth factor gene that blunts the cognitive upside of growth hormone peptides like ipamorelin.
- 5.Two people with the same goal should often take different peptides. Starting with your DNA is not optional — it's the filter that prevents wasted money.
Every peptide guide on the internet starts with the same question: what is your goal? Fat loss. Injury repair. Cognitive enhancement. Anti-aging. The goal-first approach feels logical. It is also almost certainly the wrong starting point. Your genes decide whether a given peptide works before your goals have anything to do with it, and two people with the same goal often need completely different protocols once their genetics enter the picture.
The difference in monthly weight loss rate between GLP1R rs6923761 A/A homozygotes and G-allele carriers on identical semaglutide doses, from a 2025 prospective study of 341 patients (Phan et al., Obesity, PMID 40384505). One SNP. Same drug. Same dose. Dramatically different outcomes.
This is not an argument against goals. It is an argument about sequencing. If you carry the GLP1R G-allele and start semaglutide expecting the same response as someone with A/A genotype, you will not fail because you chose the wrong dose or the wrong protocol design. You will fail because your receptor is structurally different at a molecular level. The goal was correct. The starting input was not.
A DNA-first decision framework does not replace goal-based thinking. It acts as a filter before goal-based thinking. It narrows the peptide shortlist from 20-plus candidates down to 3-5 options that are consistent with your biological architecture, then lets you apply goal logic within that constrained set.
Think of it like choosing a fuel type before planning a road trip. You would not map a 300-mile route before knowing whether you have a petrol or diesel car. Your genetics are the fuel type. Your goal is the destination. Most peptide guides hand you a map without asking what is in your tank first.
What do your genes actually predict about peptide response?
Not all genetic variants affect peptides equally. Some, like CYP3A4 variants, are more relevant to drug-interaction risk than to direct peptide response, because most research peptides are cleared proteolytically rather than by hepatic CYP enzymes. The variants with the clearest direct relevance to peptide selection fall along four biological axes. Understanding where you sit on each axis is the core of this framework.
What the GLP1R data teaches us about the whole framework
The GLP-1 peptide class has the most advanced pharmacogenomic data of any therapeutic peptide category, which makes it the best case study for why genetics must precede goal selection. A 2025 prospective study by Phan et al. in Obesity (Wiley, PMID 40384505) followed 341 patients with severe obesity on semaglutide 2.4 mg for 12 months. Patients carrying the GLP1R rs6923761 A/A genotype lost weight at 1.64 percent per month. G-allele carriers lost weight at 1.04 percent per month. That is a 58 percent difference in response rate for the same drug, same dose, same body goal, and same level of dietary compliance.
The GLP1R rs6923761 A/A genotype was associated with a significantly higher monthly rate of weight loss (1.64% vs 1.04% in G-allele carriers), representing an approximately 58% difference in weight loss velocity on semaglutide 2.4 mg. These findings suggest GLP1R genotype should be considered a clinically meaningful predictor of GLP-1 receptor agonist outcomes.
Phan et al., Obesity (Wiley), 2025, PMID 40384505
A large 2026 GWAS published in Nature, using 23andMe data from 27,885 subjects, identified GLP1R rs10305420 (p.Pro7Leu) as the first pharmacogenomically actionable locus for the entire GLP-1 class. Each copy of the effect allele predicted an additional 0.76 kg of weight loss on semaglutide or tirzepatide. The GIPR gene also predicted nausea and vomiting side effects for tirzepatide specifically. This is what mature peptide pharmacogenomics looks like at scale: two genes, two actionable decisions, before the first prescription is written.
For research peptides like BPC-157, ipamorelin, and GHK-Cu, GWAS-scale data does not yet exist. But the mechanistic inference from well-characterized variants is solid enough to be useful at a protocol level. See the semaglutide genetics guide for a deeper breakdown of GLP1R, MC4R, TCF7L2, and the related SNPs that predict response to this class.
How to map your variants to a peptide shortlist
The framework operates in two passes. The first pass uses your genetic profile to eliminate candidates. The second pass uses your goal to rank the remaining candidates. Most people skip the first pass entirely, which is why they end up cycling through three or four protocols before finding one that works.
First pass: genetic elimination
Each of the four genetic axes produces an elimination rule. These are not hard contraindications in the medical sense. They are probability statements about where your investment of time and money is most likely to produce a measurable return.
| Your variant | What it means | Deprioritize | Prioritize |
|---|---|---|---|
| COMT Met/Met | High baseline dopamine. Prefrontal cortex running warm on catecholamines. | High-dose semax, stimulating stacks without GABAergic counterbalance | Selank, low-dose semax, BPC-157 for gut-brain axis |
| COMT Val/Val | Low baseline dopamine. Fast catecholamine clearance. | Purely calming protocols, epithalon alone | Semax, BPC-157 cognitive protocol, ipamorelin for sleep recovery |
| SOD2 Val/Val | Higher oxidative burden. MnSOD activity reduced 30-40% from Ala baseline. | High-intensity stacks without antioxidant support | GHK-Cu, SS-31, BPC-157 as antioxidant adjunct |
| BDNF Met carrier | Reduced activity-dependent BDNF release. Blunted neuroplasticity response. | GH secretagogues as the primary cognitive strategy | Semax, BPC-157 neurological protocol, or a GH secretagogue stacked with a BDNF-supporting cofactor |
| GLP1R G-allele | Reduced GLP-1 receptor sensitivity. Slower metabolic response to semaglutide class. | Semaglutide as a standalone fat loss intervention | AOD-9604, MOTS-c, or combination metabolic approaches |
Second pass: goal ranking within your genetic shortlist
Once the genetic elimination pass has removed or deprioritized 3-5 peptides that are unlikely to deliver for your biology, goal logic takes over. If you are a SOD2 Val/Val carrier with elevated oxidative load and your goal is cognitive performance, both GHK-Cu and SS-31 are on the genetic shortlist and both fit the cognitive goal. You rank between them based on delivery preference, budget, and whether you want a topical or injectable approach. Goal logic is the second filter, not the first.
For a deeper look at how protocols are structured once the shortlist is established, the peptide stacking guide covers the layering logic, timing, and cycling approach that applies after genetic selection.
What can a 23andMe or AncestryDNA file actually tell you?
Consumer genomics data varies significantly in SNP coverage and imputation quality. Understanding what your raw data file contains is important before assuming you have complete information on any of the four genetic axes above.
| Gene / SNP | 23andMe v5 | AncestryDNA | MyHeritage | Coverage note |
|---|---|---|---|---|
| COMT rs4680 (Val158Met) | Yes | Yes | Yes | Directly genotyped on all major arrays. Reliable in all consumer files. |
| BDNF rs6265 (Val66Met) | Yes | Yes | Yes | Directly genotyped. Universal coverage. |
| SOD2 rs4880 (Ala16Val) | Yes | Yes | Yes | Directly genotyped. Universal coverage. |
| GLP1R rs6923761 | Yes (v5+) | Imputed | Imputed | 23andMe v5 directly genotypes this. Older kits and Ancestry rely on imputation. |
| MC4R rs17782313 | Yes | Yes | Yes | Directly genotyped on all arrays. Well-covered. |
| CYP3A4 *22 (rs35599367) | Yes (v5) | No | Imputed | Not on AncestryDNA array. Requires 23andMe v5 or a targeted pharmacogenomic test for direct reading. |
The variants on the four genetic axes above are well-covered by all major consumer genomics providers, with the exception of some CYP pharmacogenomic variants. This means most people can use existing raw data files rather than ordering a new test. For a full breakdown of what each provider covers for metabolizer phenotyping, the CYP enzymes guide includes a comparison of 23andMe, AncestryDNA, and MyHeritage genotyping depth.
The number of genetic axes (COMT, SOD2, BDNF, GLP1R/MC4R) that explain the majority of inter-individual variance in response to the most commonly used research peptides. All four are covered by consumer genomics arrays. None of them appear in any mainstream peptide selection guide.
Why right now is a useful moment to run this analysis
In April 2026, the FDA removed 12 peptide bulk drug substances from its Category 2 "do not compound" list, effective April 23, 2026. The list includes BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon (source: Orrick LLP regulatory advisory, April 2026; Frier Levitt, April 2026). These peptides are not yet approved for compounding, but they are no longer explicitly prohibited, and the FDA Pharmacy Compounding Advisory Committee is scheduled to evaluate several of them for the 503A Bulks List at a July 2026 meeting.
This regulatory shift changes who can access physician-supervised compounded protocols in the US. For anyone who has been waiting for clearer legal access before investing in a personalized protocol, the window is more open now than at any point since 2023. The genetics-first approach is particularly valuable in this context: identifying which 3-5 peptides match your biology before the prescribing conversation saves the clinical visit from becoming an expensive trial-and-error exercise.
GHK-Cu, one of the peptides with the broadest application on the SOD2 and oxidative stress axis, is currently available as a topical and injectable compound. The GHK-Cu peptide page covers mechanism, dosing, and where it fits relative to other antioxidant-modulating options.
Start with your SNP profile, then choose your peptide.
COMT, BDNF, SOD2, and GLP1R variants create four distinct genetic axes that narrow a 20-peptide catalog down to 3-5 candidates before goal logic enters the picture. A 2025 prospective study confirmed a 58% difference in semaglutide outcomes based on a single GLP1R SNP. The same principle applies across the peptide catalog, and the variants are covered by the same consumer genomics file you may already have. Upload your raw DNA file at PeptidesDNA to get a ranked peptide report built from your genetic profile, or order a saliva kit if you do not yet have genomic data.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Which peptides should I take based on my DNA?
The answer depends on four genetic axes: COMT Val158Met (catecholamine tone), SOD2 Ala16Val (oxidative stress load), BDNF Val66Met (neuroplasticity signaling), and GLP1R variants (metabolic response). COMT Met/Met carriers respond better to calming nootropic peptides like selank than to stimulating ones like high-dose semax. SOD2 Val/Val carriers show the strongest response to GHK-Cu and SS-31. BDNF Met carriers often underperform on GH secretagogues alone. A full genetic report maps all four axes against the peptide catalog and ranks candidates by predicted response.
Does my 23andMe or AncestryDNA data cover the relevant peptide SNPs?
Yes, for the four core axes. COMT rs4680, BDNF rs6265, SOD2 rs4880, and MC4R rs17782313 are directly genotyped on all major consumer arrays. GLP1R rs6923761 is directly genotyped on 23andMe v5 and imputed on older kits and AncestryDNA. CYP3A4 *22 is only directly genotyped on 23andMe v5. If you have a raw data file from any major consumer genomics provider, you can upload it to get the core peptide genetics analysis without ordering a new test.
What does COMT Val158Met mean for peptide selection?
COMT encodes the enzyme that degrades dopamine in the prefrontal cortex. Met/Met carriers have 3-4x lower COMT activity and higher baseline dopamine levels. This means stimulating nootropic protocols, including high-dose semax and dopamine-amplifying stacks, may be too activating and produce anxiety or overstimulation. Met/Met carriers typically respond better to GABAergic or serotonin-modulating peptides like selank, or lower-dose semax targeted at stress resilience rather than cognitive stimulation. Val/Val carriers have the opposite profile and generally tolerate dopamine-boosting protocols well.
How does SOD2 Ala16Val affect my peptide protocol?
SOD2 encodes manganese superoxide dismutase, the primary antioxidant enzyme in your mitochondria. The Val allele (rs4880 T allele) reduces enzyme activity by approximately 30-40% compared to the Ala variant. Val/Val carriers have a higher baseline oxidative burden and typically show the strongest measurable response to peptides with antioxidant or mitochondrial-protective mechanisms, specifically GHK-Cu and SS-31. For these individuals, addressing oxidative stress genetically is often the highest-yield first move before layering in repair or nootropic peptides.
Why might semaglutide not work as well for me as for someone else?
The most well-studied reason is GLP1R rs6923761 genotype. A 2025 prospective study (Phan et al., Obesity, PMID 40384505) showed A/A homozygotes lost weight 58% faster per month than G-allele carriers on the same semaglutide dose. A 2026 Nature GWAS of 27,885 subjects also identified GLP1R rs10305420 as a pharmacogenomically actionable locus, with each effect allele predicting additional weight loss. If you carry G-allele variants and are seeing minimal response on semaglutide, your receptor sensitivity to this drug class may be genuinely reduced at a genetic level rather than being a behavioral or compliance issue.
What is BDNF Val66Met and why does it matter for cognitive peptides?
BDNF Val66Met (rs6265) is a common variant affecting the trafficking of brain-derived neurotrophic factor. Met allele carriers, approximately 20-30% of the population, have impaired activity-dependent BDNF secretion. This matters for cognitive peptide selection because growth hormone secretagogues like ipamorelin and CJC-1295 work partly by elevating IGF-1, which drives downstream BDNF signaling. Met carriers may see blunted cognitive benefits from GH secretagogues because their BDNF release machinery is impaired upstream of the IGF-1 signal. These individuals often respond better to direct BDNF-modulating approaches like semax or to BPC-157 in neurological protocols.
Do I need a new genetic test or can I use my existing 23andMe data?
For the four primary genetic axes relevant to peptide selection, existing 23andMe (v4 or v5), AncestryDNA, or MyHeritage raw data files are sufficient. COMT, BDNF, SOD2, and MC4R are all directly genotyped on these platforms. GLP1R rs6923761 is directly genotyped on 23andMe v5 and imputed on others. The only gap is some CYP pharmacogenomic variants like CYP3A4 *22, which requires 23andMe v5 or a targeted pharmacogenomic test. If you do not yet have any genetic data, a saliva kit provides complete coverage for all relevant peptide SNPs.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.